U.S. Carboprost Tromethamine Market Size, Share & Forecast 2026–2032

ID: MR-11704 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Carboprost Tromethamine Market
  • ✓Market Size 2024: USD 112 million
  • ✓Market Size 2032: USD 158 million
  • ✓CAGR: 4.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Generic Price Erosion Accelerating: Group purchasing organizations award carboprost contracts on unit price, and generic vials from Dr. Reddy's and Long Grove have pushed hospital acquisition costs well below Pfizer's Hemabate list price. Hemabate retains share only where obstetric formularies lock in brand supply.
FINDING 02
Medicaid Extension Overstated as Driver: Consensus treats the Medicaid postpartum coverage extension under the American Rescue Plan Act of 2021 as a volume driver. Carboprost volume follows inpatient hemorrhage protocols under Joint Commission standards, not coverage duration, so the extension adds marginal growth.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Dual-Source Supply Contracts: Hospital pharmacy directors should contract dual-source carboprost supply with at least two ANDA holders by Q1 2026. Single-source interruptions, reportable under Section 506C, leave obstetric units without a validated uterotonic alternative, so contracts signed now protect procedure continuity.

Carboprost Tromethamine in the United States: Market Overview

The U.S. carboprost tromethamine market is a small, hospital-centered injectable segment valued at USD 112 million in 2024. Carboprost, a prostaglandin F2α analogue, is indicated for postpartum hemorrhage due to uterine atony and for second-trimester termination of pregnancy, and it is supplied as a 250 mcg per mL vial that must be refrigerated. The market's structure was set by FDA approval of Pfizer's Hemabate under NDA 017989, which created a single-brand market for decades before the Hatch-Waxman generic pathway opened it to competition.

Government has shaped this market mainly through reimbursement and labeling rather than direct procurement. CMS pays for carboprost administered in hospitals under Medicare Part B at average sales price plus 6 percent under Section 1847A of the Social Security Act, while HRSA's 340B Drug Pricing Program lets safety-net hospitals buy it at discounted prices. The private sector leads on manufacturing and pricing, with Pfizer holding the reference brand and ANDA holders including Dr. Reddy's Laboratories and Long Grove Pharmaceuticals supplying a growing share of vials.

Policy-Driven Growth in US Carboprost Tromethamine

The American Rescue Plan Act of 2021, Section 9812, extended Medicaid postpartum coverage from 60 days to 12 months in states adopting the option, effective April 2022. Medicaid finances roughly 41 percent of U.S. births, so longer coverage keeps more hemorrhage-risk patients under obstetric care during the period when postpartum uterine atony is most likely, widening the population for which carboprost is indicated.

The Preventing Maternal Deaths Act of 2018, Public Law 115-344, funded state maternal mortality review committees that classify postpartum hemorrhage as a leading preventable cause of death. Those findings push hospitals toward standardized hemorrhage bundles, which list carboprost as a second-line uterotonic and convert policy attention into routine pharmacy stocking.

Regulatory Barriers and Compliance Costs

FDA approval of a generic carboprost requires an abbreviated new drug application demonstrating bioequivalence and sterile-injectable manufacturing compliance under 21 CFR Parts 210 and 211, administered by the Office of Generic Drugs within the Center for Drug Evaluation and Research. Sterile fill-finish facilities face unannounced inspections, and a Form 483 observation or warning letter can halt shipments for months, adding 18 to 30 months to market entry for new applicants.

Supply-chain rules add recurring cost. The Drug Supply Chain Security Act of 2013 requires product identifiers and transaction history for each package, with the final electronic interoperability phase due November 2026, and smaller distributors bear software costs. Section 506C of the Federal Food, Drug, and Cosmetic Act requires manufacturers to notify FDA at least six months before discontinuing a product, and failure to notify exposes manufacturers to enforcement.

Policy-Created Opportunities in the United States

HRSA's Title V Maternal and Child Health Services Block Grant funds state programs that equip rural obstetric units with hemorrhage kits, creating a demand pathway in facilities that currently stock little carboprost. Suppliers that register their vials on state-funded hemorrhage kit lists gain volume without competing for hospital formulary slots.

FDA's 505(b)(2) pathway allows a sponsor to file a ready-to-use prefilled syringe formulation referencing Hemabate, avoiding full clinical trials. Prefilled presentations suit the emergency obstetric kits favored under Joint Commission medication safety standards, and 340B contract pharmacy arrangements offer a second channel for suppliers with that formulation.

Market at a Glance

MetricValue
Market Size 2024USD 112 million
Market Size 2032USD 158 million
Growth Rate (CAGR)4.4%
Most Critical Decision FactorANDA approval timing and hospital formulary acceptance of generic supply
Largest RegionSouth Census Region
Competitive StructureOligopolistic: brand reference product plus concentrated ANDA holders

Leading Market Participants

  • Pfizer
  • Dr. Reddy's Laboratories
  • Long Grove Pharmaceuticals
  • Amneal Pharmaceuticals
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Sagent Pharmaceuticals
  • Eugia US
  • Gland Pharma
  • Meitheal Pharmaceuticals

Regulatory and Policy Environment

The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act, with the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) setting the generic entry route. FDA's Center for Drug Evaluation and Research and its Office of Generic Drugs administer approvals, CMS administers Medicare Part B and Medicaid Drug Rebate Program reimbursement under Section 1927 of the Social Security Act, and HRSA administers the 340B program under Section 340B of the Public Health Service Act. Manufacturers must maintain FDA establishment registration and DSCSA transaction data.

Upcoming changes include the DSCSA full interoperability deadline in November 2026, which requires trading partners to exchange electronic product data, and the inflation rebate provisions of the Inflation Reduction Act of 2022, which apply to Part B drugs whose prices rise faster than inflation. Compared with regional peers, the U.S. framework is more fragmented than Canada's provincial listing system under Health Canada, and less harmonized than the EU's Falsified Medicines Directive, which already requires pack-level verification through the European Medicines Verification System.

Long-Term Policy Outlook for U.S. Carboprost Tromethamine

Between now and 2032, the most consequential policy change will be the Medicaid postpartum extension. Pending federal bills would make the 12-month coverage permanent, and CMS has encouraged states to adopt it fully. Permanence would stabilize the postpartum patient pool and convert a temporary demand lift into a structural base for carboprost volume across Medicaid-funded births.

Dobbs v. Jackson Women's Health Organization (2022) returned abortion regulation to the states, so second-trimester termination demand for carboprost will diverge sharply by state. Restrictive regimes such as Texas Senate Bill 8 will shrink volume, while permissive states sustain it. Combined with generic price erosion, growth will settle near 4.4 percent a year, with value shifting toward suppliers holding redundant ANDA capacity and FDA-compliant sterile manufacturing.

Frequently Asked Questions

The FDA's Office of Generic Drugs within the Center for Drug Evaluation and Research reviews abbreviated new drug applications for generic carboprost. Approval requires demonstrated bioequivalence to Hemabate and compliant sterile-injectable manufacturing.
The DSCSA requires serialized product identifiers and electronic transaction data at each distribution step. The final interoperability phase is due in November 2026, and smaller distributors face the highest software compliance costs.
Section 506C requires manufacturers to notify FDA at least six months before discontinuing a product. Timely notification allows FDA to list shortages and helps hospitals secure alternative supply.
CMS reimburses Part B drugs at average sales price plus 6 percent under Section 1847A of the Social Security Act. Hospitals therefore pay acquisition cost and recover a margin tied to manufacturer pricing.
The American Rescue Plan Act of 2021 extended Medicaid postpartum coverage to 12 months in adopting states. Coverage extends the patient population under obstetric care, but hospital protocols rather than coverage duration determine actual carboprost use.

Market Segmentation

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Birthing Centers
  • Academic Medical Centers
  • Federal Facilities
By Distribution Channel
  • Group Purchasing Organizations
  • Wholesale Distributors
  • Specialty Distributors
  • 340B Contract Pharmacies
By Product Type
  • Brand-Name Hemabate
  • ANDA Generics
  • Authorized Generics
  • Prefilled Syringe Formulations

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Carboprost Tromethamine - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 End User Insights
4.1 Hospitals
4.2 Ambulatory Surgical Centers
4.3 Birthing Centers
4.4 Academic Medical Centers
4.5 Others
Chapter 05 Distribution Channel Insights
5.1 Group Purchasing Organizations
5.2 Wholesale Distributors
5.3 Specialty Distributors
5.4 340B Contract Pharmacies
5.5 Others
Chapter 06 Product Type Insights
6.1 Brand-Name Hemabate
6.2 ANDA Generics
6.3 Authorized Generics
6.4 Prefilled Syringe Formulations
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Pfizer
7.2.2 Dr. Reddy's Laboratories
7.2.3 Long Grove Pharmaceuticals
7.2.4 Amneal Pharmaceuticals
7.2.5 Hikma Pharmaceuticals
7.2.6 Fresenius Kabi
7.2.7 Sagent Pharmaceuticals
7.2.8 Eugia US
7.2.9 Gland Pharma
7.2.10 Meitheal Pharmaceuticals
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.